EU drugs regulator backs higher dose of Novo's Wegovy

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.

Reuters • Dec 12, 2025

Novo Nordisk launches blockbuster diabetes drug Ozempic in India

Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday.

Reuters • Dec 12, 2025

Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

Novo Nordisk has officially launched Ozempic in India, marking a significant expansion of its presence in one of the world's fastest-growing markets for diabetes and obesity treatments. The launch comes at a time when demand for weight-loss drugs is rising sharply, driven by lifestyle changes, urbanisation, and increasing awareness of metabolic health.

Invezz • Dec 12, 2025

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)

GlobeNewsWire • Dec 12, 2025

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.

Zacks Investment Research • Dec 12, 2025

Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut.

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

Barrons • Dec 12, 2025

Why Novo Nordisk Stock Topped the Market on Thursday

A bipartisan bill has been introduced in the U.S. Congress that would curb some activities of compound pharmacies. The maker of Wegovy has been particularly affected by competition from such parties.

The Motley Fool • Dec 12, 2025

Novo Nordisk (NVO) Laps the Stock Market: Here's Why

Novo Nordisk (NVO) closed at $50.29 in the latest trading session, marking a +2.53% move from the prior day.

Zacks Investment Research • Dec 11, 2025

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment.

CNBC • Dec 11, 2025

Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.

Zacks Investment Research • Dec 10, 2025